Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study

Article activity feed

1. Version published to 10.1016/j.eclinm.2022.101576

   Sep 1, 2022
2. 

   ScreenIT

   Apr 2, 2022

   SciScore for 10.1101/2022.03.30.22273175: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Consent: Informed consent was obtained from the residents, or their relatives when the residents did not have full capacity to sign legal documents.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Detection of past infection relied on anti-Spike (S) and anti-Nucleocapsid (N) antibodies for pre-vaccination sera, and only on anti-N antibodies for post-vaccination sera.	anti-Spike (S) suggested: None anti-Nucleocapsid (N) suggested: None anti-N suggested: None
   Briefly, this assay uses 293T cells stably expressing the Spike (S) protein (293T-S cells) and …

   SciScore for 10.1101/2022.03.30.22273175: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Consent: Informed consent was obtained from the residents, or their relatives when the residents did not have full capacity to sign legal documents.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Detection of past infection relied on anti-Spike (S) and anti-Nucleocapsid (N) antibodies for pre-vaccination sera, and only on anti-N antibodies for post-vaccination sera.	anti-Spike (S) suggested: None anti-Nucleocapsid (N) suggested: None anti-N suggested: None
   Briefly, this assay uses 293T cells stably expressing the Spike (S) protein (293T-S cells) and 293T control cells as control to detect anti-Spike antibodies by flow cytometry [20].	anti-Spike suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Briefly, this assay uses 293T cells stably expressing the Spike (S) protein (293T-S cells) and 293T control cells as control to detect anti-Spike antibodies by flow cytometry [20].	293T suggested: RRID:CVCL_LC70) 293T-S suggested: RRID:CVCL_LC70)
   Viral stock were produced on Vero E6 cells, titrated on Vero E6 or S-Fuse cells and sequenced to confirm viral lineages (GISAID accession ID: EPI_ISL_2029113 and EPI_ISL_7413964 for Delta and Omicron isolates, respectively).	Vero E6 suggested: None
   Software and Algorithms
   Sentences	Resources
   The assay is standardized with WHO international reference sera (20/136 and 20/130) and cross-validated with two commercially available ELISA (Abbott 147 and Beckmann 56) to allow calculation of BAU/mL [22].	Abbott suggested: (Abbott, RRID:SCR_010477)
   This assay uses U2OS-ACE2 GFP1-10 and GFP 11 reporter cells, also termed S-Fuse cells, that become GFP+ upon infection with SARS-CoV-2 [23,24].	SARS-CoV-2 suggested: (Active Motif Cat# 91351, RRID:AB_2847848)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Our study has limitations. First, the small sample size limits our statistical power and precludes analysis of the characteristics that may further impact vaccine efficacy, such as gender, prexisting conditions or ongoing medications. Second, we did not have access to nasopharyngeal swabs to measure antibody levels at the site of viral entry and replication. We were thus unable to link breakthrough infections to local levels of antibodies, which might represent a better correlate of protection. Further studies are needed to determine the contribution of mucosal immunity on the acquisition of SARS-CoV-2 and the severity of COVID-19. Lastly, we only tested BA.1, the initial Omicron clade, which was circulating in France at the time of the investigation and was responsible of the breaktrough infections that occurred in the nursing homes of the study. It will be worth examining the neutralization activity of the sera against other Omicron sub-lineages, such as BA.2, at the next blood sampling of the same cohort participants. This study confirmed the importance of receiving at least three antigenic exposures to the Spike protein for achieving satisfactory neutralizing antibody levels against Omicron. Protection against Omicron was increased in those who had been previously infected in addition to the three doses, suggesting that a fourth antigenic exposure may be useful in this elderly population to prevent infection with a variant known for its high escape immunity properties.

   ---

   Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
   

   Identifier	Status	Title
   NCT04644159	Recruiting	Longitudinal Follow-up of a Population Cohort in a French Ci…

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a protocol registration statement.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2022.03.30.22273175v1 on medRxiv

   Mar 30, 2022